Movement Alert｜Gilead Sciences Falls 3.03% in Regular Trading, Q2 Acquisition-Driven R&D Charges Swing Results to Loss Despite Revenue Beat

Market Focus08-05 22:49

On August 5, Gilead Sciences declined 3.03% in regular trading, trading at $130.87/share, with turnover of $527 million. The selloff followed the company's Q2 earnings release after market close on August 4.

Gilead reported Q2 revenue of $7.80 billion, up 10% year-over-year and above the $7.4 billion consensus estimate. Adjusted EPS came in at a loss of $6.75, better than the expected loss of $7.24. However, the company swung from a profit of $2.01 per share a year ago to a significant loss, driven by $9.08 per share in intellectual property R&D and tax charges related to recent acquisitions. Additionally, COVID-19 treatment Veklury saw sales plunge 81% to $23 million, prompting management to slash full-year Veklury guidance from approximately $600 million to $300 million. Executives also noted that the cancellation of ACA tax subsidies caused some patients to lose insurance coverage, softening the HIV treatment market in Q2. The company raised full-year HIV growth guidance to 9%-10% from 8%, and narrowed its full-year adjusted loss forecast to $0.30-$0.65 per share versus the prior range of $0.65-$1.05.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1149003616?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 22:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149003616","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Gilead Sciences Falls 3.03% in Regular Trading, Q2 Acquisition-Driven R&D Charges Swing Results to Loss Despite Revenue Beat","media":"Market Focus","content":"<p><p>On August 5, Gilead Sciences declined 3.03% in regular trading, trading at $130.87/share, with turnover of $527 million. The selloff followed the company's Q2 earnings release after market close on August 4.</p><p>Gilead reported Q2 revenue of $7.80 billion, up 10% year-over-year and above the $7.4 billion consensus estimate. Adjusted EPS came in at a loss of $6.75, better than the expected loss of $7.24. However, the company swung from a profit of $2.01 per share a year ago to a significant loss, driven by $9.08 per share in intellectual property R&D and tax charges related to recent acquisitions. Additionally, COVID-19 treatment Veklury saw sales plunge 81% to $23 million, prompting management to slash full-year Veklury guidance from approximately $600 million to $300 million. Executives also noted that the cancellation of ACA tax subsidies caused some patients to lose insurance coverage, softening the HIV treatment market in Q2. The company raised full-year HIV growth guidance to 9%-10% from 8%, and narrowed its full-year adjusted loss forecast to $0.30-$0.65 per share versus the prior range of $0.65-$1.05.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Gilead Sciences Falls 3.03% in Regular Trading, Q2 Acquisition-Driven R&D Charges Swing Results to Loss Despite Revenue Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Gilead Sciences Falls 3.03% in Regular Trading, Q2 Acquisition-Driven R&D Charges Swing Results to Loss Despite Revenue Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-05 22:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 5, Gilead Sciences declined 3.03% in regular trading, trading at $130.87/share, with turnover of $527 million. The selloff followed the company's Q2 earnings release after market close on August 4.</p><p>Gilead reported Q2 revenue of $7.80 billion, up 10% year-over-year and above the $7.4 billion consensus estimate. Adjusted EPS came in at a loss of $6.75, better than the expected loss of $7.24. However, the company swung from a profit of $2.01 per share a year ago to a significant loss, driven by $9.08 per share in intellectual property R&D and tax charges related to recent acquisitions. Additionally, COVID-19 treatment Veklury saw sales plunge 81% to $23 million, prompting management to slash full-year Veklury guidance from approximately $600 million to $300 million. Executives also noted that the cancellation of ACA tax subsidies caused some patients to lose insurance coverage, softening the HIV treatment market in Q2. The company raised full-year HIV growth guidance to 9%-10% from 8%, and narrowed its full-year adjusted loss forecast to $0.30-$0.65 per share versus the prior range of $0.65-$1.05.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"","article_id":"1149003616","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149003616","pubTimestamp":1785941397,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 5, Gilead Sciences declined 3.03% in regular trading, trading at $130.87/share, with turnover of $527 million. The selloff followed the company's Q2 earnings release after market close on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学"},"translate_title":"走势警报|吉利德科学在常规交易中下跌 3.03%，尽管收入超出预期，但第二季度收购驱动的研发费用仍导致业绩亏损","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":1},"content_text":"On August 5, Gilead Sciences declined 3.03% in regular trading, trading at $130.87/share, with turnover of $527 million. The selloff followed the company's Q2 earnings release after market close on August 4.Gilead reported Q2 revenue of $7.80 billion, up 10% year-over-year and above the $7.4 billion consensus estimate. Adjusted EPS came in at a loss of $6.75, better than the expected loss of $7.24. However, the company swung from a profit of $2.01 per share a year ago to a significant loss, driven by $9.08 per share in intellectual property R&D and tax charges related to recent acquisitions. Additionally, COVID-19 treatment Veklury saw sales plunge 81% to $23 million, prompting management to slash full-year Veklury guidance from approximately $600 million to $300 million. Executives also noted that the cancellation of ACA tax subsidies caused some patients to lose insurance coverage, softening the HIV treatment market in Q2. The company raised full-year HIV growth guidance to 9%-10% from 8%, and narrowed its full-year adjusted loss forecast to $0.30-$0.65 per share versus the prior range of $0.65-$1.05.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1149003616","isCrawlerRequest":true}